DarioHealth reports Q2 EPS (58c), consensus (52c)

Reports Q2 revenue $6.15M, consensus $6.46M. “During the second quarter, we saw a continuation of the many positive trends that have contributed to our improved financial profile, including growing revenue contribution from highly scalable Business-to-Business (“B2B”) customers, expanding gross margins, and reduced operating expenses, as compared to the same period last year,” stated Erez Raphael, CEO of Dario. “Of note, we increased our gross profit margin to 33.7% in the second quarter of 2023 compared to 18.4% in the second quarter of 2022. Our proforma gross margins increased to 51.5% in the second quarter of 2023, up significantly from 36.1% in the second quarter of 2022, while reducing our operating expense run rate by 13% over that period.”